Impatients NV

AMSTERDAM, Sept. 4, 2024 /PRNewswire/ -- myTomorrows, a global health technology company connecting patients with all possible treatment options, today announced a new partnership with the CureLGMD2i Foundation, a non-profit organization whose mission is to spread awareness, provide advocacy, and raise funds to research and support patients suffering from Limb Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9). Under the new partnership, CureLGMD2i will leverage myTomorrows' extensive search engine of ongoing clinical trials to provide patients, caregivers and healthcare professionals with up-to-date, accessible information about pre-approval treatments that may be relevant to them, as well as support while engaging with these treatments. LGMD2I/R9 is a rare form of Muscular Dystrophy, a group of progressively debilitating diseases that cause profound muscle wasting and weakness. LGMD2I/R9 mainly affects the shoulder, thigh and hip muscles, and patients suffering from the disease are at a higher risk of cardiovascular, respiratory and overall mobility challenges. With no cure currently available for LGMD2I/R9, it is imperative for patients to stay well-informed about their treatment options, particularly clinical trials, which are often challenging to find, understand, and navigate. The new partnership will help to raise awareness of potential treatment options among LGMD2I/R9 patients, their families and healthcare providers (HCPs), while also easing the process of identifying and understanding existing clinical trial options. Patients and physicians will be able to easily use myTomorrows' search engine of worldwide clinical trials to search for relevant LGMD2I/R9 pre-approval treatment options. myTomorrows' expert patient navigators will help to demystify the complex terminology around clinical trials and support patients and their loved ones throughout the process, enabling them to make the most informed decisions possible about their treatment. "We are thrilled to be partnering with CureLGMD2i to help raise awareness of clinical trials among patients with LGMD2I/R9, their loved ones, and the physicians who treat them," said Dr. Michel van Harten, CEO of myTomorrows. "This collaboration advances our commitment to empowering patients and HCPs with confidence and knowledge throughout their treatment journeys. As the biopharma industry increasingly seeks to develop further treatments for this genetic disease, we will continue to ensure that those affected are armed with the up-to-date information they need to make the decisions that suit them best." "Our vision is a future where individuals affected by this rare disease can receive early treatment and live unburdened by its challenges," said Kelly Brazzo, CEO and co-founder of CureLGMD2i. "We look forward to continuing to further this mission with the help of myTomorrows, providing support for our community of patients and their families and enhancing their ability to access and utilize pre-approval treatment options." Patients, their caregivers, and physicians can learn more about available clinical trials for Limb Girdle Muscular Dystrophy Type 2I/R9 here. About myTomorrows: myTomorrows is a global healthtech company dedicated to breaking down barriers for patients seeking treatment options. To make this a reality, the company has built powerful technology that enables a comprehensive search of clinical trials databases worldwide, efficiently connecting patients, physicians, trial sites and BioPharma to support straightforward and transparent access to drugs in development. Headquartered in Amsterdam with an office in New York City, myTomorrows has helped more than 11,000 patients and 2,000 physicians in over 40 countries to date. myTomorrows media contact: Ben Crome Headline Media [email protected] +1 914 336 4922 About CureLGMD2i: The CureLGMD2i Foundation was created by the Brazzo Family when their daughter, Samantha, was diagnosed with Limb Girdle Muscular Dystrophy Type 2I/R9 at the age of two. At that time, there were no FDA approved therapies for LGMD2I/R9. They created this 501(c)3 Nonprofit Organization (formerly known as The Samantha J. Brazzo Foundation) with a mission to spread awareness, provide advocacy for the patient community, and to raise funds to support research for LGMD2I/R9. CureLGMD2i media contact: Kelly Brazzo [email protected] SOURCE myTomorrows

The partnership aims to enhance access to clinical trials for patients suffering from pancreatic cancer by leveraging myTomorrows’ extensive database of ongoing trials. Pancreatic cancer is notoriously challenging to treat, with a life expectancy of only 6-12 months at the time of diagnosis and a five-year survival rate of just 10%. The disease is difficult to diagnose early, often resistant to conventional treatments like chemotherapy and radiation, and has limited treatment options available. Given these challenges, the company emphasized the importance of ensuring that patients, caregivers, and healthcare professionals are well-informed about all potential treatment avenues, including clinical trials. The partnership will facilitate easier access to trial information through a new clinical trial search tool that will be featured on the Pancreatic Cancer Europe website. This tool will simplify the process of finding relevant clinical trials from the myTomorrows database, making it easier for patients and healthcare providers to navigate potential treatment options. The company’s expert patient navigators will also be available to assist in understanding and accessing these trials, offering support to patients and their families throughout the process. Pancreatic cancer awareness “We are very excited to be partnering with Pancreatic Cancer Europe, an organisation that works tirelessly to raise awareness of pancreatic cancer, promote advancements in treatments, and empower European member organisations to better address the relevant issues regarding the disease,” said Dr Michel van Harten, CEO of myTomorrows. googletag.cmd.push(function () { googletag.display('text-ad1'); }); “Collaborating with leading patient advocacy groups like PCE helps us extend our reach to more patients in need and empower them to navigate their treatment journeys with more confidence and knowledge, while enabling pharmaceutical companies to expand access throughout the drug development cycle.” Pancreatic Cancer Europe expressed similar optimism about the partnership. “This new partnership is an important step in the persistent fight against pancreatic cancer,” said Professor Alfredo Carrato, chair of Pancreatic Cancer Europe. “The innovative myTomorrows platform will support patients suffering from pancreatic cancer, their caregivers, and their treating physicians by significantly easing the process of accessing and navigating clinical trials, another opportunity for them, enabling a more informed and proactive approach to treatment of this devastating disease.” The collaboration between myTomorrows and Pancreatic Cancer Europe represents a concerted effort to address the critical need for accessible and accurate information about treatment options for pancreatic cancer patients, potentially offering new hope in the fight against this aggressive disease.

Partnership with the European patient advocacy group furthers myTomorrows' mission to expand access to all possible treatment options for patients suffering from a variety of life-threatening illnesses AMSTERDAM, Aug. 27, 2024 /PRNewswire/ -- myTomorrows, a global health technology company connecting patients with all possible treatment options, today announced a new partnership with Pancreatic Cancer Europe, a multi-stakeholder platform that brings together experts from all over Europe with a common interest and willingness to improve care for patients with pancreatic cancer. Through the new partnership, Pancreatic Cancer Europe (PCE) will utilize myTomorrows' vast database of ongoing clinical trials to equip patients, caregivers and healthcare professionals with up-to-date, accessible information about pre-approval treatments that may be relevant to them. Pancreatic cancer is the fourth leading cause of cancer deaths, with a life expectancy of only 6-12 months at time of diagnosis and a 5-year survival rate of only 10%. The many challenges associated with pancreatic cancer include a lack of awareness about the disease among the public, difficulty in diagnosis, which is late, treatment resistance to chemo and radiation therapy, poor survival rates, and limited treatments. Therefore, it is crucial for patients to be as accurately and thoroughly informed as possible about their treatment options – especially clinical trials, which are often difficult to find, understand, and navigate. For pancreatic cancer patients, their loved ones, and the Health Care Professionals (HPCs) who treat them, the partnership will ease the process of identifying and understanding the existing clinical trial options. In doing so, it will enable them to make the best possible decisions about their treatment, with myTomorrows' expert patient navigators demystifying the complexities of clinical trials and supporting patients and their families throughout the process. A new clinical trial search tool, which will be featured on the Pancreatic Cancer Europe website, will make it even easier and quicker to search for relevant treatment options across myTomorrows' vast database of ongoing clinical trials worldwide. "We are very excited to be partnering with Pancreatic Cancer Europe, an organisation that works tirelessly to raise awareness of pancreatic cancer, promote advancements in treatments, and empower European member organisations to better address the relevant issues regarding the disease," said Dr. Michel van Harten, CEO of myTomorrows. "Collaborating with leading patient advocacy groups like PCE helps us extend our reach to more patients in need and empower them to navigate their treatment journeys with more confidence and knowledge, while enabling pharmaceutical companies to expand access throughout the drug development cycle." "This new partnership is an important step in the persistent fight against pancreatic cancer," said Prof. Alfredo Carrato, Chair of Pancreatic Cancer Europe. "The innovative myTomorrows platform will support patients suffering from pancreatic cancer, their caregivers and their treating physicians by significantly easing the process of accessing and navigating clinical trials, another opportunity for them, enabling a more informed and proactive approach to treatment of this devastating disease." To learn more about available clinical trials and the people impacted by pancreatic cancer including patients, their caregivers, and physicians click here. About myTomorrows: myTomorrows is a global healthtech company dedicated to breaking down barriers for patients seeking treatment options. To make this a reality, the company has built powerful technology that enable a comprehensive search of clinical trials databases worldwide, efficiently connecting patients, physicians, trial sites and BioPharma to support straightforward and transparent access to drugs in development. Headquartered in Amsterdam with an office in New York City, myTomorrows has helped more than 5,000 patients and 500 physicians in over 80 countries to date. myTomorrows Media Contact: Ben Crome Headline Media [email protected] +1 914 336 4922 About Pancreatic Cancer Europe: Pancreatic Cancer Europe is a European multi-stakeholder platform which aims at bringing together experts from all over Europe including academics, physicians, politicians, patient groups and journalists with a common interest and willingness to improve care for patients with pancreatic cancer. Pancreatic Cancer Europe Media Contact: Priya Raja Communication Officer [email protected] SOURCE myTomorrows